Glyphic Biotechnologies develops Protein Sequencing by Expansion (ProSE™), a novel technology for high-throughput proteome sequencing. This method achieves single-molecule sensitivity for accurate discrimination of all 20 amino acids and post-translational modifications (PTMs). The platform aims to provide unprecedented precision and scalability for advancing proteomics research and therapeutic development.
Funding
$43.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+5Founders
Product
Problem
Current methods for protein sequencing are limited by low throughput, high error rates, and challenges in accurately identifying post-translational modifications. These limitations hinder the development of targeted therapeutics and diagnostics that rely on precise protein characterization.
Solution
Glyphic Biotechnologies is developing a next-generation protein sequencing platform designed to enhance binding affinity and consistency, enabling more accurate and efficient protein analysis. The platform aims to overcome limitations of existing methods by providing higher throughput, reduced error rates, and improved identification of post-translational modifications. This technology will allow researchers to gain deeper insights into protein structure and function, accelerating the development of personalized cancer vaccines and other targeted therapeutics. By improving the accuracy and efficiency of protein sequencing, Glyphic Biotechnologies seeks to advance the understanding of human biology and disease.
Target Audience
The primary target audience includes researchers and scientists in the fields of proteomics, drug discovery, and personalized medicine, particularly those focused on cancer research and vaccine development.
Features
- Enhanced binding affinity for improved protein capture and sequencing accuracy
- High-throughput sequencing capabilities for rapid protein analysis
- Improved identification of post-translational modifications
- Development of personalized cancer vaccines
- Targeted therapeutics and diagnostics